MannKind Corporation has announced the appointment of Alejandro Galindo as Chief Commercial Officer. Galindo most recently headed the Intensive Insulin Management business unit at Medtronic and previously served in a number of roles at GE Healthcare.
In addition to marketing its Afrezza inhaled insulin, which was approved by the FDA in 2014, MannKind is partnered with United Therapeutics on development of an inhaled dry powder treprostinil for the treatment of pulmonary arterial hypertension and has a range of DPI candidates in its pipeline. Earlier this year, MannKind announced that it would refocus its R&D efforts on the treatment of COVID-19, in particular, a DPI development project with Immix Biopharma.
MannKind CEO Michael Castagna said, “We are excited to welcome Alejandro to MannKind during a critical period of growth. He is an exceptional addition to our executive leadership team and will be a tremendous asset to us as we continue to expand our commercial organization. I’m confident that Alejandro’s strong leadership skills and extensive experience in product development, global expansion, diabetes, and distribution strategy will help position us for success in the future.”
Galindo said, “I’m thrilled to join such an innovative company that is committed to transforming the standard of care for insulin-dependent diabetes and orphan lung diseases. I know MannKind has a bright future ahead, and I look forward driving the commercial strategy and expanding access to novel treatment options for patients with unmet medical needs.”
Read the MannKind Corporation press release.
